Merkel Cell Carcinoma
95
19
37
25
Key Insights
Highlights
Success Rate
58% trial completion
Published Results
16 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.9%
18 terminated out of 95 trials
58.1%
-28.4% vs benchmark
3%
3 trials in Phase 3/4
64%
16 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (95)
A Study of CRD3874-SI in People With Solid Tumors
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
TIL Therapy in cSCC and MCC
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )